The injectable drug delivery market encompasses a wide range of features, applications, and uses. Its key features include precise dosage control, targeted drug delivery, and rapid onset of action. Applications span various medical fields, including oncology, diabetes, cardiovascular diseases, and autoimmune disorders. Injectable drug delivery systems are used to administer medications, vaccines, and biologics directly into the bloodstream or specific body tissues. They offer benefits such as improved patient compliance, reduced side effects, and enhanced therapeutic outcomes, making them vital in modern healthcare for efficient and effective drug administration.
Access Full Report: https://www.databridgemarketresearch.com/reports/global-injectable-drug-delivery-market
Data Bridge Market Research analyses that the Global Injectable Drug Delivery Market is valued at USD 17.13 billion in 2021 and is expected to reach USD 46.84 billion by 2029, registering a CAGR of 13.40% during the forecast period of 2022 to 2029. Fiber optic gyroscopes find applications in industrial automation, robotics, and precision engineering. They enable precise control of robotic systems, improve accuracy in manufacturing processes, and enhance stability in industrial equipment which drives the market’s growth.
Key Findings of the Study
The increasing prevalence of chronic diseases is expected to drive the market's growth rate
The increasing prevalence of chronic diseases, such as diabetes, cardiovascular diseases, and cancer, drives the growth of the healthcare market. Chronic diseases often require long-term treatment, including frequent medication administration. Injectable drug delivery systems provide a convenient and effective way to manage these conditions. The growing patient population with chronic diseases creates a higher demand for injectable drug delivery solutions, contributing to the overall market growth in the healthcare industry.
Report Scope and Market Segmentation
|
Report Metric
|
Details
|
|
Forecast Period
|
2022 to 2029
|
|
Base Year
|
2021
|
|
Historic Years
|
2020 (Customizable to 2014-2019)
|
|
Quantitative Units
|
Revenue in USD Billion, Volumes in Units, Pricing in USD
|
|
Segments Covered
|
Type (Injectable Drug Delivery Devices, Injectable Drug Delivery Formulation), Formulation Packaging (Ampoules, Vials, Cartridges, Bottles), Therapeutic Application (Autoimmune Diseases, Hormonal Disorders, Orphan Diseases, Cancer, Others), Usage Pattern (Curative Care, Immunization, Other), Site Of Administration (Skin, Circulatory/Musculoskeletal System, Organs, Central Nervous System), Distribution Channel (Hospital, Retail Pharmacy Stores), End User (Hospitals and Clinics, Home Care Settings, Others)
|
|
Countries Covered
|
U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America.
|
|
Market Players Covered
|
Abbott (U.S.), B.D. (U.S.), Novartis AG (Switzerland), Pfizer Inc. (U.S.), Baxter (U.S.), Gerresheimer AG (Germany), AstraZeneca (U.K.), Terumo Medical Corporation (Japan), Teva Pharmaceutical Industries Ltd.(Jerusalem), Eli Lilly and Company (U.S.), Schott AG (Germany), Sanofi (France), Johnson & Johnson Private Limited (U.S.), Mylan N.V. (U.S.), West Pharmaceutical Services, Inc. (U.S.), SHL Medical AG (Switzerland), Insulet Corporation (U.S.), E3D Elcam Drug Delivery Devices (Israel), Ypsomed AG (Switzerland), AbbVie Inc. (U.S.), Novo Nordisk A/S (Denmark)
|
|
Data Points Covered in the Report
|
In addition to the insights on market scenarios such as market value, growth rate, segmentation, geographical coverage, and major players, the market reports curated by the Data Bridge Market Research also include depth expert analysis, patient epidemiology, pipeline analysis, pricing analysis, and regulatory framework
|
Segment Analysis:
The injectable drug delivery market is segmented on the basis of type, formulation packaging, therapeutic application, usage pattern, site of administration, distribution channel, and end user.
- On the basis of type, the injectable drug delivery market is segmented into injectable drug delivery devices and injectable drug delivery formulation. In 2022 the injectable drug delivery formulation market is expected to dominate at the highest CAGR of 11.5% in the forecasted period 2022 to 2029 as they help solubilize drugs that are not readily soluble or stable in their pure form, allowing for their effective delivery through injection.
In 2022, the injectable drug delivery formulation segment is dominating the type segment of the global injectable drug delivery market
In 2022, the injectable drug delivery formulation segment is dominating the market as formulations assist in preserving the stability of drugs by preventing degradation or chemical reactions, ensuring the medication's efficacy and shelf life. They allow for the combination of multiple drugs in a single injectable formulation, enabling the simultaneous administration of different medications for enhanced therapeutic outcomes.
- On the basis of formulation packaging, the injectable drug delivery market is segmented into ampoules, vials, cartridges, and bottles. In 2022 ampoules segment dominates injectable drug delivery as they help in maintaining accurate dosing and reduce the risk of contamination or wastage.
- On the basis of therapeutic application, the injectable drug delivery market is segmented into autoimmune diseases, hormonal disorders, orphan diseases, cancer, and others. In 2022, the hormonal disorders segment is expected to dominate the market with 50.1% market share as injectable drug delivery plays is widely used in the treatment of growth hormone deficiencies, especially in children.
- On the basis of usage pattern, the injectable drug delivery market is segmented into curative care, immunization and others. In 2022 the curative care is expected to dominate the market at the highest CAGR of 12.5% in the forecast period as injectable drug delivery allows for precise dosing, ensuring that the medication reaches the intended target and achieves the desired therapeutic effect.
- On the basis of site of administration, the injectable drug delivery market is segmented into skin, circulatory/musculoskeletal system, organs and central nervous system. In 2022, skin is the most common and the highest growing segment with the highest 12.8% CAGR in the forecast period as it plays crucial role in curative care by providing effective and targeted administration of medications to treat various diseases and conditions
In 2022, skin is dominating the site of administration of the global injectable drug delivery market
In 2022 skin segment is dominating the site of administration segment of the global injectable drug delivery market as injectable drug delivery systems designed for the skin, such as subcutaneous injections, offer convenience, patient acceptance, and self-administration capabilities. They are widely used for the treatment of chronic conditions like diabetes, autoimmune diseases, and hormonal disorders. The skin segment also plays a crucial role in delivering biologics and peptide therapies, providing targeted delivery, and offering long-acting formulations
- On the basis of distribution channel, the injectable drug delivery market is segmented into hospital and retail pharmacy stores. In 2022 hospital segment dominated the market due to the extensive use of injectable medications in hospital settings for various treatments, surgeries, emergency care, and critical conditions, ensuring accurate dosing and effective delivery of medications to patients.
- On the basis of end user, the injectable drug delivery market is segmented hospitals and clinics, home care settings and others. In 2022 hospital segment dominated the market as utilize a wide range of injectable medications for inpatient care, surgeries, emergency treatments, and critical conditions
Major Players
Data Bridge Market Research recognizes the following companies as the major injectable drug delivery market players in injectable drug delivery market are Abbott (U.S.), B.D. (U.S.), Novartis AG (Switzerland), Pfizer Inc. (U.S.), Baxter (U.S.), Gerresheimer AG (Germany), AstraZeneca (U.K.)
Market Developments
- In January 2022, West has entered into a significant collaboration with Corning Incorporated in the field of pharmaceutical injectable drug delivery. This collaboration aims to leverage Corning's Valor Glass technology to enhance packaging and delivery systems for injectable drugs in the pharmaceutical industry. The primary objective is to improve patient safety and expand the availability of critical therapies, ensuring more patients can access life-saving treatments.
- In 2022, Becton, Dickinson, and Company have launched the BD Ultrasafe Plus 2.25 ml Passive Needle Guard, a specialized device for drug-device combination products. By pairing it with a Glass Prefillable Syringe, healthcare professionals can safely administer biological solutions of different volumes (up to 2ml) and viscosities (up to 30 cP). This advancement offers a dependable and effective method for delivering medications, prioritizing patient safety and providing healthcare providers with a trusted solution.
- In Aug 2019, Becton, Dickinson, and Company have introduced the BD Ultrasafe Plus 2.25 ml Passive Needle Guard, an innovative device designed specifically for drug-device combination products. When used alongside a Glass Prefillable Syringe, this system enables healthcare professionals to securely deliver biological solutions of varying volumes (up to 2ml) and viscosities (up to 30 cP). This advancement ensures the safe administration of medications, placing patient safety at the forefront and offering healthcare providers a reliable solution they can trust.
- In September 2021, Antares Pharma, Inc. has initiated a phase 1 study for ATRS-1902, a potential solution for adrenal crisis rescue. The study focuses on evaluating the effectiveness of the treatment in adults and adolescents with acute adrenal insufficiency. The innovative approach involves utilizing a proprietary auto-injector platform to deliver a liquid form of hydrocortisone. The aim of this program is to provide a convenient and effective treatment option for individuals experiencing adrenal crisis.
- In November 2021, Becton, Dickinson, and Company have introduced the BD Ultrasafe Plus 2.25 ml Passive Needle Guard, specifically designed for drug-device combination products. This innovative system, when used with a Glass Prefillable Syringe, allows for the safe administration of biological solutions with varying volumes up to 2ml and viscosities of up to 30 cP. This development provides healthcare professionals with a reliable and efficient solution for delivering medications while ensuring patient safety.
Regional Analysis
Geographically, the countries covered in the injectable drug delivery market report are U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America.
As per Data Bridge Market Research analysis:
North America is the dominant region in the injectable drug delivery market during the forecast period 2022 - 2029
In 2022, North America dominated the injectable drug delivery market is attributed to the increasing adoption of advanced injectable drug delivery systems, driven by the need for effective and targeted drug administration. The presence of a large patient pool with chronic conditions requiring injectable medications further contributes to market growth. Moreover, the rising expenditure on healthcare infrastructure and facilities enhances the accessibility and availability of injectable drug delivery systems, fueling the market's expansion in the region.
Asia-Pacific is estimated to be the fastest growing region in the injectable drug delivery market in the forecast period 2022 - 2029
In 2022, Asia-Pacific is expected to grow during the forecast period due to rising awareness among healthcare professionals and patients about the benefits of injectable drug delivery systems. As awareness increases, there is a greater recognition of the advantages such as accurate dosing, targeted delivery, and improved patient compliance. Additionally, the region is witnessing an increasing number of patients requiring injectable medications due to the rising prevalence of chronic diseases, contributing to the expansion of the market.
For more detailed information about the injectable drug delivery market report, click here – https://www.databridgemarketresearch.com/reports/global-injectable-drug-delivery-market
